medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 6

<< Back Next >>

Ann Hepatol 2015; 14 (6)

Predicting early discharge from hospital after liver transplantation (ERDALT) at a single center: a new model

Piñero F, Fauda M, Quiros R, Mendizabal M, González-Campaña A, Czerwonko D, Barreiro M, Montal S, Silberman E, Coronel M, Cacheiro F, Raffa P, Andriani O, Silva M, Podestá LG

Language: English
References: 31
Page: 845-855
PDF size: 126.79 Kb.


ABSTRACT

Background & rationale. Limited information related to Liver Transplantation (LT) costs in South America exists. Additionally, costs analysis from developed countries may not provide comparable models for those in emerging economies. We sought to evaluate a predictive model of Early Discharge from Hospital after LT (ERDALT = length of hospital stay ≤ 8 days). A predictive model was assessed based on the odds ratios (OR) from a multivariate regression analysis in a cohort of consecutively transplanted adult patients in a single center from Argentina and internally validated with bootstrapping technique. Results. ERDALT was applicable in 34 of 289 patients (11.8%). Variables independently associated with ERDALT were MELD exception points OR 1.9 (P = 0.04), surgery time ‹ 4 h OR 3.8 (P = 0.013), ‹ 5 units of blood products consumption (BPC) OR 3.5 (P = 0.001) and early weaning from mechanical intubation OR 6.3 (P = 0.006). Points in the predictive scoring model were allocated as follows: MELD exception points (absence = 0 points, presence = 1 point), surgery time ‹ 4 h (0-2 points), ‹ 5 units of BPC (0-2 points), and early weaning (0-3 points). Final scores ranged from 0 to 8 points with a c-statistic of 0.83 (95% CI 0.77-0.90; P ‹ 0.0001). Transplant costs were significantly lower in patients with ERDALT (median $23,078 vs. $28,986; P ‹ 0.0001). Neither lower patient and graft survival, nor higher rates of short-term re-hospitalization and acute rejection events after discharge were observed in patients with ERDALT. In conclusion, the ERDALT score identifies patients suitable for early discharge with excellent outcomes after transplantation. This score may provide applicable models particularly for emerging economies.


REFERENCES

  1. Lucey MR, Terrault N, Ojo L, Hay JE, Neuberger J, Blumberg E, Tepperman LW, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 2012; 19: 3-26.

  2. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ. Liver Transplantation in the United States, 1999-2008. Am J Transplant 2010; 10: 1003-19.

  3. Thuluvath PJ, Krok KL, Segev DL, Yoo HY. Trends in post– liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States. Liver Transpl 2007; 13: 719-24.

  4. Adam RE, McMaster P, O apos Grady JG, Castaing D, Klempnauer JL, Jamieson N, Nehaus P, et al. Evolution of liver transplantation in Europe: Report of the European Liver Transplant Registry. Liver Transpl 2003; 9: 1231-43.

  5. Duffy JP, Kao K, Ko CY, Farmer DG, McDiarmid SV, Hong JC, Busuttil R. Long-Term Patient Outcome and Quality of Life After Liver Transplantation. Ann Surg 2010; 252: 652-61.

  6. Knight M, Barber K, Gimson A, Collett D, Neuberger J, for the Liver Advisory Group of National Health Service Blood Transplant. Implications of changing the minimal survival benefit in liver transplantation. Liver Transpl 2012; 18: 549-57.

  7. Wai H, Stepanova M, Saab S, Erario M, Srishord M, Younossi ZM. Inpatient Economic and Mortality Assessment for Liver Transplantation. Transplantation 2014; 97: 98- 103.

  8. Rando K, Niemann CU, Taurà P, Klinck J. Optimizing costeffectiveness in perioperative care for liver transplantation: A model for low- to medium-income countries. Liver Transpl 2011; 17: 1247-78.

  9. Kelly DM, Bennett R, Brown N, McCoy J, Boerner D, Yu C, Fung J. Predicting the discharge status after liver transplantation at a single center: A new approach for a new era. Liver Transpl 2012; 18: 796-802.

  10. Macomber CW, Shaw JJ, Santry H, Saidi RF, Jabbour N, Tseng JF, Shah S, et al. Centre volume and resource consumption in liver transplantation. HPB 2012; 14: 554-9.

  11. Krishnan KR, Bhattacharya R, Pereira A, Otto AK, Carithers RL Jr, Reyes JD, Perkins JD, et al. The HALOS-ND model: a step in the journey of predicting hospital length of stay after liver transplantation. Clin Transplant 2013; 27: 809-22.

  12. Salvalaggio PR, Dzebisashvili N, MacLeod KE, Lentine KL, Gheorghian A, Schnitzler MA, Axelrod DA, et al. The interaction among donor characteristics, severity of liver disease, and the cost of liver transplantation. Liver Transpl 2011; 17: 233-42.

  13. Washburn WK, Meo NA, Halff GA, Roberts JP, Feng S. Factors influencing liver transplant length of stay at two largevolume transplant centers. Liver Transpl 2009; 15: 1570-8.

  14. Hepp J, Innocenti FA. Liver transplantation in Latin America: Current status. Transplantation Proceedings 2004; 36: 1667-8.

  15. Neil DAH, Hubscher SG. Current views on rejection pathology in liver transplantation. Transplant Int 2010; 23: 971-83.

  16. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43.

  17. Yao FY. Liver Transplantation for Hepatocellular Carcinoma: Beyond the Milan Criteria. Am J Transplant 2008; 8: 1982-9.

  18. Toso C, Trotter J, Wei A, Bigam DL, Shah S, Lancaster J, Grant DR, et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2008; 14: 1107-15.

  19. Vibert E, Azoulay D, Hoti E, Iacopinelli S, Samuel D, Salloum C, Lemoine A, et al. Progression of Alphafetoprotein Before Liver Transplantation for Hepatocellular Carcinoma in Cirrhotic Patients: A Critical Factor. Am J Transplant 2009; 10: 129-37.

  20. Ravaioli M, Grazi GL, Piscaglia F, Trevisani F, Cescon M, Ercolani G, Vivarelli M, et al. Liver Transplantation for Hepatocellular Carcinoma: Results of Down-Staging in Patients Initially Outside the Milan Selection Criteria. Am J Transplant 2008; 8: 2547-57.

  21. Yao FY, Kerlan RK Jr., Hirose R, Davern TJ III, Bass NM, Feng S, Peters M, et al. Excellent outcome following downstaging of hepatocellular carcinoma prior to liver transplantation: An intention-to-treat analysis. Hepatology 2008; 48: 819-27.

  22. Biancofiore GG, Bindi MLM, Romanelli AMA, Boldrini AA, Bisà MM, Esposito MM, Urbani L, et al. Fast track in liver transplantation: 5 years’ experience. Eur J Anaesthesiol 2005; 22: 584-90.

  23. Foxton MR, Al-Freah MAB, Portal AJ, Sizer E, Bernal W, Auzinger G, Rela M, et al. Increased model for end-stage liver disease score at the time of liver transplant results in prolonged hospitalization and overall intensive care unit costs. Liver Transpl 2010; 16: 668-77.

  24. Taner CB, Willingham DL, Bulatao IG, Shine TS, Peiris P, Torp KD, Canabal J, et al. Is a mandatory intensive care unit stay needed after liver transplantation? Feasibility of fast-tracking to the surgical ward after liver transplantation. Liver Transpl 2012; 18: 361-9.

  25. Bulatao IG, Heckman MG, Rawal B, Aniskevich S, Shine TS, Keaveny AP, Perry DK, et al. Avoiding Stay in the Intensive Care Unit After Liver Transplantation: A Score to Assign Location of Care. Am J Transplant 2014; 14: 2088-96.

  26. Earl TM, Cooil B, Rubin JE, Chari RS. Cost Prediction in Liver Transplantation Using Pretransplant Donor and Recipient Characteristics. Transplantation 2008; 86: 238-44.

  27. Axelrod DA, Schnitzler M, Salvalaggio PR, Swindle J, Abecassis MM. The Economic Impact of the Utilization of Liver Allografts with High Donor Risk Index. Am J Transplant 2007; 7: 990-7.

  28. Cejas NG, Villamil FG, Lendoire JC, Tagliafichi V, Lopez A, Krogh DH, Soratti C, et al. Improved Waiting-List Outcomes in Argentina After the Adoption of a Model for End- Stage Liver Disease-Based Liver Allocation Policy. Liver Transpl 2013; 19: 711-20.

  29. Bruns H, Hillebrand N, Schneider T, Hinz U, Fischer L, Schmidt J, Schemmer P, et al. LabMELD-based organ allocation increases total costs of liver transplantation: a single-center experience. Clin Transplant 2011; 25: E558- E565.

  30. Buchanan P, Dzebisashvili N, Lentine KL, Axelrod DA, Schnitzler MA, Salvalaggio PR. Liver transplantation cost in the model for end-stage liver disease era: Looking beyond the transplant admission. Liver Transpl 2009; 15: 1270-7.

  31. Piñero F, Marciano S, Villamil A, Bandi J, Casciato P, Galdame O, Gadano A, et al. Sicker Patients for Liver Transplantation: Meld, Meld Sodium, and Integrated Meld’s Prognostic Accuracy in the Assessment of Posttransplantation Events at a Single Center from Argentina. ISRN Transplantation 2013; 2013: 1-7.




2020     |     www.medigraphic.com